Use of Apoptotic Biomarkers to Predict Response to Radiotherapy in Breast Cancer Patients
Authors
Abstract:
Introduction: To enhance radiation therapy efficiency it is crucial to implement an individual-based treatment. The aim of present study was to identify the mechanism of intrinsic apoptosis pathway on radiosensitivity and normal tissue complications caused by the radiotherapy. Materials and Methods: radiation-induced apoptosis in peripheral blood mononuclear cells derived from unselected breast cancer (BC) patients was examined using the relative quantitative RT-PCR. Expression levels of Bax, Bcl-2, and Bax/Bcl-2 ratio (as an in-vitro radiosensitivity index (RSI)) were examined in in-vitro irradiated (1 and 2 Gy) cells. All the patients received similar tangential irradiation of the whole breast and conventional fractionation and then, Clinical radiosensitivity (as a clinical radiosensitivity index) was determined using the acute reactions to radiotherapy of the skin according to RTOG score. All statistical analyses were performed using GraphPad Prism, version 7.01. Results: The notable result was a significant correlation between dose-response curve slope (in-vitro RSI) and acute skin toxicity score following irradiation (clinical RSI). Conclusion: These data suggest that Bax/Bcl-2 ratio determination before radiation therapy can be used as a potential biomarker to identify radiosensitive individuals. However, further studies are required to validate radiation-induced apoptotic biomarkers.
similar resources
Bax/Bcl-2 expression ratio in prediction of response to breast cancer radiotherapy
Objective(s): Radiotherapy is one of the most effective modalities of cancer therapy, but clinical responses of individual patients varies considerably. To enhance treatment efficiency it is essential to implement an individual-based treatment. The aim of present study was to identify the mechanism of intrinsic apoptosis pathway on radiosensitivity and normal tissue complications caused by the ...
full textA comparison of contralateral breast dose due to breast cancer radiotherapy using two different treatment machines in a radiotherapy center
Background: The radiation dose received by contralateral breast (CLB) is one of the concerns of breast radiotherapy, because it may lead to the induction of secondary breast cancer. The aim of this study was to evaluate the CLB surface dose in the breast treatment in Yazd radiotherapy center. Materials and Methods: The surface dose of CLB was measured using TLD dosimetry in 50 cancer breast pat...
full textImaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
PURPOSE To evaluate noninvasive imaging methods as predictive biomarkers of response to trastuzumab in mouse models of HER2-overexpressing breast cancer. The correlation between tumor regression and molecular imaging of apoptosis, glucose metabolism, and cellular proliferation was evaluated longitudinally in responding and nonresponding tumor-bearing cohorts. EXPERIMENTAL DESIGN Mammary tumor...
full textBiomarkers to Predict Antidepressant Response
During the past several years, we have achieved a deeper understanding of the etiology/pathophysiology of major depressive disorder (MDD). However, this improved understanding has not translated to improved treatment outcome. Treatment often results in symptomatic improvement, but not full recovery. Clinical approaches are largely trial-and-error, and when the first treatment does not result in...
full textfrom linguistics to literature: a linguistic approach to the study of linguistic deviations in the turkish divan of shahriar
chapter i provides an overview of structural linguistics and touches upon the saussurean dichotomies with the final goal of exploring their relevance to the stylistic studies of literature. to provide evidence for the singificance of the study, chapter ii deals with the controversial issue of linguistics and literature, and presents opposing views which, at the same time, have been central to t...
15 صفحه اولBiomarkers and response to therapy in breast cancer.
To the Editor: Yang and colleagues (1) describe an elegant study investigating molecular markers that are hypothesized to predict clinical benefit from the use of bevacizumab in breast cancer. This research is both timely and pertinent, given the ongoing questions surrounding the benefit conferred by the addition of bevacizumab to taxane-based chemotherapy in breast cancer (2). The data suggest...
full textMy Resources
Journal title
volume 15 issue Special Issue-12th. Iranian Congress of Medical Physics
pages 42- 42
publication date 2018-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023